CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 78 enrolled
Drug / intervention
Lidocaine Hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03720119
NCT03720119N/ACompleted
CompareCT.gov

Multicentre Observational Study on the Wound Pain Relief Properties of ORTODERMINA®

SOFAR S.p.A.·observational·Posted Oct 25, 2018·Updated Apr 12, 2023

In Brief

An observational study evaluating Lidocaine Hydrochloride for Wound Healing Disorder. Completed, enrolled 78 participants across 2 sites.

Detailed Summary

Acute pain may occur due to trauma, surgery, infection, disruption of blood circulation or when there is tissue injury. It can be managed using analgesics and conduction anaesthesia, which may be preferable because of superior pain control and fewer side effects. Lidocaine hydrochloride is used topically to relieve itching, burning and pain from skin inflammation. This multicentric observational study is aimed to evaluate the relief gained with lidocaine hydrochloride (ORTODERMINA®) on wound pain in patients with painful wounds and to collect safety information on this treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsWound Healing Disorder
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 25, 2018
Enrollment StartJan 27, 2015
Primary CompletionMar 5, 2018
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.7 years ago

Interventions

Lidocaine Hydrochloridedrug

As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.